Clemastine fumarate (cas 14976-57-9) as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
-
Add time:07/16/2019 Source:sciencedirect.com
SummaryBackgroundMultiple sclerosis is a degenerative inflammatory disease of the CNS characterised by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in the CNS is a specialised extension of the oligodendrocyte plasma membrane and Clemastine fumarate (cas 14976-57-9) can stimulate differentiation of oligodendrocyte precursor cells in vitro, in animal models, and in human cells. We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis.
We also recommend Trading Suppliers and Manufacturers of Clemastine fumarate (cas 14976-57-9). Pls Click Website Link as below: cas 14976-57-9 suppliers
Prev:Mono and diphosphine borane complexes grafted on polypyrrole matrix: direct use as supported ligands for Rh and Pd catalysis
Next:Highly photoluminescent label free probe for Chromium (II) ions using carbon quantum dots co-doped with nitrogen and phosphorous) - 【Back】【Close 】【Print】【Add to favorite 】